<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578668</url>
  </required_header>
  <id_info>
    <org_study_id>GZTO1201</org_study_id>
    <nct_id>NCT01578668</nct_id>
  </id_info>
  <brief_title>Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases</brief_title>
  <official_title>Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether erlotinib plus pemetrexed, cisplatin are
      effective and safe in treating lung adenocarcinoma with brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-small lung cancer (NSCLC) is the leading cause of death in the world. Brain metastases
      are a frequent complication of NSCLC, especially in lung adenocarcinoma. 30-50% or more these
      patients will develop brain metastases at first time or during the treatment. Limited
      treatment options, whole brain radiotherapy (WBRT) combined with or without stereotactic
      radiosurgery (SRS) as the primary treatment approach, are available for brain metastases
      patients with poor survival. So the availability of effective therapies are therefore of
      great importance. Currently, two agents (erlotinib and pemetrexed) are reported more
      effective in lung adenocarcinoma patients with brain metastases. The heterogeneity of NSCLC
      tumors provides a strong rationale for using combination therapy with targeted agents that
      have different mechanisms of action, moreover different combination offering synergistic
      effects. So we investigate if erlotinib plus pemetrexed, cisplatin are effective and safe in
      treating lung adenocarcinoma with brain metastases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate of brain metastases</measure>
    <time_frame>Patients will be followed for an expected average of 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The disease control response rate of disease</measure>
    <time_frame>Patients will be followed for an expected average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of patients</measure>
    <time_frame>2 years after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>2 years after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients</measure>
    <time_frame>3 years after the first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD</description>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles</description>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <other_name>ALIMTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin 20mg/m² iv on the 1st-3rd day (if PS&lt;2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles</description>
    <arm_group_label>Erlotinib, pemetrexed, cisplatin</arm_group_label>
    <other_name>platinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg given orally (po), daily (QD), starting on the first day of the first cycle</description>
    <arm_group_label>erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological diagnosis of lung adenocarcinoma histology with brain
             metastases

          2. 18 years or older

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 3 (poor PS
             caused by neurological symptom)

          4. Appraisable intracranial disease, the presence of at least one lesion, and the longest
             diameter &gt; 5 mm by brain MRI

          5. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x 10^9/L

          6. Total bilirubin 1.5 x upper limit of normal (ULN)

          7. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 x ULN in the
             absence of liver metastases, or &lt; 5 x ULN in case of liver metastases

          8. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)

          9. If received brain radiotherapy, patients included at least 8 weeks after the end of
             radiotherapy.

        Exclusion Criteria:

          1. Mixed non-adenocarcinoma cell lung cancer histology

          2. Previous treatment with pemetrexed or tarceva

          3. Be allergic to pemetrexed or tarceva
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haihong Yang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first affiliated hospital of Guangzhou MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangzhou MC</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Haihong Yang, MD, Pricipal investigator</investigator_full_name>
    <investigator_title>The first affiliated hospital of Guangzhou MC</investigator_title>
  </responsible_party>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>brain metastases</keyword>
  <keyword>erlotinib</keyword>
  <keyword>pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

